Delayed life-threatening pneumonitis secondary to procarbazine.
A patient with advanced Hodgkin's disease being treated with MOPP chemotherapy presented with delayed life-threatening pulmonary toxicity secondary to procarbazine. The pulmonary toxicity began 1 week after procarbazine had been discontinued and once recognized was successfully treated with intravenous steroids.
Brooks
B J
BJ
Ochsner Clinic of Baton Rouge, Louisiana 70816.
Hendler
N B
NB
Alvarez
S
S
Ancalmo
N
N
Grinton
S F
SF
D000328:Adult; D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced* / Q000175:diagnosis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007877:Legionnaires' Disease / Q000175:diagnosis; D008466:Mechlorethamine / Q000008:administration & dosage; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone